➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
AstraZeneca
McKinsey
Mallinckrodt
Express Scripts

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Litigation Details for Pfizer Inc. v. Mylan Inc. (D. Del. 2010)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Pfizer Inc. v. Mylan Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .
Biologic Drugs cited in Pfizer Inc. v. Mylan Inc.
The biologic drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Pfizer Inc. v. Mylan Inc. (D. Del. 2010)

Date Filed Document No. Description Snippet Link To Document
2010-06-16 1 Complaint infringement of U.S. Patent Nos. 6,573,293 (“the ’293 patent”), 7,125,905 (“the ’905 patent”) and 7,211,600… Letter. COUNT I - INFRINGEMENT OF U.S. PATENT NO. 6,573,293 36. Plaintiffs repeat and reallege each…one or more claims of the ’293 patent, the ’905 patent, and the ’600 patent, which have been listed in connection…title, and interest in the ’293 patent, the ’905 patent, and the ’600 patent, including the right to sue …to the expiration of the ’293 patent, the ’905 patent, and the ’600 patent. 34. In the Notice Letter, External link to document
2012-02-21 103 Order ORDER Construing the Terms of U.S. Patent Nos. 6,573,293 and 7,211,600. Signed by Chief Judge Gregory…2010 23 October 2014 1:10-cv-00528 830 Patent None District Court, D. Delaware External link to document
2013-02-06 153 POST Trial Brief and 21 of U.S. Patent No. 6,573,293 (“the ’293 patent”) and claims 1 and 2 of U.S. Patent No. 7,125,905…defense were considered by the Patent Office before issuing the patents-in-suit. Ex. 1 at 2-9; Ex. 2 at…06/13 Page 4 of 48 PageID #: 4099 In re ’318 Patent Infringement Litig., 578 F. Supp. 2d 711 (D…..........39, 40 In re Alfuzosin Hydrochloride Patent Litig., 2010 WL 1956287 (D. Del. May 14, 2010….................27 In re Rosuvastatin Calcium Patent Litig., -- F.3d --, 2012 WL 6217356 (Fed. Cir External link to document
2014-10-22 163 C. The Patents-in-Suit 1. U.S. Patent Number 6,573,293 ("the '293 patent")--"… the '293 patent, was filed on February 15, 2001 with the United States Patent and Trademark …expiration date ofthe '293 patent is February 15, 2021. 4. The '293 patent lists ten inventors on its…October 27, 2000. 7. U.S. Patent Number 7,125,905 ("the '905 patent")--"Pyrrole Substituted…expiration date of the '905 patent is February 15, 2021. 10. The '905 patent lists ten inventors on its External link to document
2010-06-17 4 Patent/Trademark Report to Commissioner the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,573,293 B2; US 7,125,905 …2010 23 October 2014 1:10-cv-00528 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Express Scripts
McKesson
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.